Unidad de Cáncer de Pulmón

Unidad de Cáncer de Pulmón

​​

 

  • A randomized phase III trial with anti PD 1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS). Investigador Principal Ana Collazo.

 

 

 

  • A phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex 14) skipping alterations after failure of al least one prior active therapy, incluiding a platinum-deublet containing regimen. Investigador Principal Javier de Castro.

     
  • Phase 2 Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)"  Investigador Principal Javier de Castro

     
  • A PHASE II MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NSCLC HARBORING ACTIONABLE SOMATIC MUTATIONS ETECTED IN BLOOD. Investigador Principal Javier de Castro

 

  • A  RANDOMIZED, OPEN-LABER, MULTICENTER STUDY COMPARING THE EFFICACY, SAFETY AND TOLERABILITY OF ROVALPITUZUMAB TESIRINE VERSUS TOPOTECAN FOR HIGH DLL3 EXPRESSIN SCLC SUBJECTS WITH FIRST RELAPSE/RECURRENCE FOLLOWING FRONT-LINE PLATINUM-BASED CHEMOTHERAPY. Investigador Principal Beatriz Jimenez

 

 

  • A phase III, open -label, randomized study to evaluate the efficacy  anda safety of adjuvant alectinib versus adjuvant platinum-based chemotherapy in patients with completely resected stage IB (Tumor > 4cm) to stage IIIA anaplastic lymphoma Kinase-positive Non-Small Cell Lung Cancer. Investigador Principal Ana Collazo

     
  • T790M mutation testing in blood by different methodologies. Investigador Principal Ana Collazo

     

     
  • An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer. IO102-012 Investigador Principal Javier de Castro.

     
  • A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an ammune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectable malgnant pleural mesthelioma. Investigador Principal Beatriz Jimenez

 

 



To Top